To prevent S. aureus infections after surgical procedures three methods were described, i.e. isolation precautions after MRSA screening, vancomycin as antibiotic prophylaxis in patients at risk for MRSA and topical decolonisation of carriage. Identified MRSA carriers can be treated with the appropriate antibiotic prophylaxis to prevent infection with MRSA. Topical decolonisation with chlorhexidine gluconate resulted in a reduced overall nosocomial infection rate, but no effect was found on the S. aureus infection rate. Topical decolonisation with mupirocin reduced the overall S. aureus infection rate after surgery in S. aureus nasal carriers.
Purpose of review
The present review describes the literature about the prevention of S. aureus infections in surgery, published from August 2006 until January 2008 and puts it into perspective.
Recent findings
To prevent S. aureus infections after surgical procedures three methods were described, i.e. isolation precautions after MRSA screening, vancomycin as antibiotic prophylaxis in patients at risk for MRSA and topical decolonisation of carriage. Identified MRSA carriers can be treated with the appropriate antibiotic prophylaxis to prevent infection with MRSA. Topical decolonisation with chlorhexidine gluconate resulted in a reduced overall nosocomial infection rate, but no effect was found on the S. aureus infection rate. Topical decolonisation with mupirocin reduced the overall S. aureus infection rate after surgery in S. aureus nasal carriers.
Summary
Treatment of proven carriers of S. aureus with mupirocin is an effective method to prevent S. aureus nosocomial infections after surgery. Cost-analysis studies show that this screen-and-treat approach is cost-saving as long as the prevalence of mupirocin resistance in S. aureus is low. The effect of chlorhexidine gluconate on the S. aureus infection rate in carriers should be determined in future studies.
Background
Staphylococcus aureus is the most important pathogen after surgical procedures.
Although historically the focus has been on the control of cross infection, most infections are caused by strains that are carried by the patient on admission to the hospital. Nasal carriage of S. aureus is a well-known risk factor for subsequent infection in patients undergoing surgery. 1 New developments, like real-time PCR, enable detection of the nasal carriage status in <2 hours, which makes it possible to identify and treat carriers before they are operated. 2 This study showed that nasal carriage is an important risk factor for the development of a SSI with S. aureus, which had been shown in other studies before.
Routine MRSA screening and intra operative antimicrobial prophylaxis with an alternative prophylactic regiment like selective decontamination of the digestive tract were excluded. 991 patients were randomized, 500 to the chlorhexidine group and 491 to the placebo group. Of these, 15 patients discontinued treatment, which resulted in analysis of 485 and 469 patients in the treatment and placebo group, respectively. 22 patients were excluded later from analysis becaused they received preoperative selective deontamination of the digestive tract after inclusion. Follow-up was complete in all patients and identical in both groups. Both groups received an oropharyngeal rinse and a nasal ointment containing either chlorhexidine gluconate or placebo. The oropharyngeal solution (10ml) was used as a mouth rinse and applied to buccal, pharyngeal, gingival, and tooth surfaces for 30 seconds 4 times daily. The nose ointment was applied 4 times a day in both nostrils. The protocol was continued until the nasogastric tube was removed, usually the day after surgery. Before intervention, there was no difference in the number of patients with S. aureus nasal carriage between treatment and placebo group (36.5% and 30.7%, respectively). At the time of the operative procedure, the number of S. aureus carriers in the treatment group was reduced from 36.5% to 15.5% (p<0.001), resulting in an Absolute Risk Reduction (ARR) of 37.5% (95% CI 27.7%-47.3%). In the placebo group no significant difference in S. aureus carriage rate was found between cultures taken at admission (30.7%) and those taken at surgery (24.5%). Primary outcome measure was the overall incidence of nosocomial infection, using the criteria developed by the Centres For Disease Control and Prevention. Secondary outcomes included the incidence of lower respiratory tract infection (LRTI) and SSI, S aureus nasal carriage, nonprophylactic antimicrobial use, duration of hospital stay, in-hospital mortality, and trial medication adverse effects.
96 patients (19.8%) in the chlorhexidine gluconate group developed 116 nosocomial infections compared with 123 patients (26.2%) with 164 nosocomial infections in the placebo group (ARR 6.4%, 95% CI 1.1-11.7%, p=0.002). Patients in the treatment group developed significant less LRTI than patients in the placebo group (n=45 versus n=74, p=0.002). Incidence of overall SSI was 9.9% in the chlorhexidine gluconate group and 10.9% in the placebo group, which did not differ significantly. However, less deep SSI were observed in the treatment group (n=9 versus n=24, p=0.002). Patients treated with placebo suffered more often from a bacteraemia than patients treated with chlorhexidine gluconate (n=17 versus n=9, p=0.001 ). An adverse effect from chlorhexidine gluconate was observed in 1 patient (0.2%) who experienced temporary minor discoloration of the teeth. Duration of hospital stay and in-hospital mortality did not differ between treatment and placebo group. This study looked at the overall nosocial infection rate, but did not look specifically at the S. aureus infection rate. However, they mentioned the micro-organisms found in cultures from patients with LRTI and SSI.
Using the Chi-square test, no statistical difference in S. aureus infection rate (both LRTI and SSI) was found between the treatment and placebo group.
Mupirocin treatment
Recently, two systematic reviews about the effect of mupirocin on the S. aureus SSI rate were performed. 8*,9** Trautmann et al. analyzed 4 randomized trials and seven sequential cohort studies investigating mupirocin nasal treatment for prophylaxis of SSI in elective surgery in comparison with placebo or no treatment. 8* Mupirocin application schemes varied widely, although there was no correlation between the duration of mupirocin treatment and reduction in SSIs. They concluded that mupirocin prophylaxis did not reduce the S. aureus SSI rate in patients undergoing orthopedic, gastrointestinal and cardiothoracic surgery. In contrast, mupirocin prophylaxis before surgery reduced the SSI rate due to MRSA and was therefore recommended in countries with high prevalences of MRSA. The weaknesses of this study are that non-English papers were excluded and that no analysis of the effect in carriers only was made.
In the review of Van Rijen et al., the effect of intranasal mupirocin on the nosocomial S. aureus infection rate after surgery was studied in patients with S. aureus nasal carriage. 9** This in contrast to Trautmann et al., who studied the effect in both patients with and without carriage. 8* Their search resulted in 3 randomized placebo-controlled trials and 1 randomized trial in which no placebo was used. Among the 686 mupirocintreated surgical patients with S. aureus nasal carriage, there were 25 S. aureus infections (3.6%), compared with 46 (6.7%) in the controls (RR 0.55, 95% CI 0.34-0.89; p=0.002). Although mupirocin reduced the overall occurrence of nosocomial S. aureus infections, no significant reduction on surgical site infections caused by S. aureus was seen (RR 0.64, 95% CI 0.38-1.06). The limit of this study is the fact that the outcome is mainly determined by the results of the study of Perl et al., because they had the largest study group. 10 They conclude that pre-operative mupirocin can be considered when the S. aureus infection rate is high compared to literature, despite adequate infection control measures.
Cost-effectiveness
Recently, two cost-effectiveness analyses about screening and decolonisation of S. aureus were performed. 11**,12* Young et al compared three strategies, (1) to have 52% sensitivity and 85% specificity. Second, a baseline efficacy rate of 56.5% for decolonisation of S. aureus was selected. Third, treatment would be initiated prior to the scheduled hospital admission and would last for 5-10 days. The probability of S. aureus infections in S. aureus nasal carriers was estimated at 7.5% and in patients without nasal carriage at 1.5%. The costs for rapid testing was assumed to be $25 and for decolonisation treatment $72.5. Based on this model the cost savings in the year 2004 were estimated at $231,538,400. The mean number of hospital-days was reduced by 364,919, and a mean of 935 in-hospital deaths due to S. aureus infection could be avoided.
Conclusion
Several approaches to prevent S. aureus infections after surgery were described, which are mainly targeted at prevention of endogeneous infections. MRSA screening and subsequent isolation measures protect other patients and health care workers from being colonised and/or infected with MRSA and the index patient benefits by prescription of appropriate antibiotics. Vancomycin is recommended as antibiotic prophylaxis in patients at risk for MRSA, while topical decolonisation with mupirocin is recommended as prophylaxis for patients with S. aureus nasal carriage. This screen-and-treat approach was proven to be cost-saving. Chlorhexidine gluconate reduced the overall nosocomial infection rate, but no significant effect on the S. aureus infection rate was observed.
The future control of S. aureus (including MRSA) in surgical patients should focus on effective prevention of endogenous infection. Mupirocin nasal ointment and chloorhexidin are potential candidates. A placebo controlled ranodomized trial in carriers only is needed to determine the effectiveness of such a strategy.
